Insider Monkey
GE HealthCare Technologies Inc. (GEHC): A Bull Case Theory
📈
AI Sentiment
Highly Positive
9/10
- Home
- GEHC
as of 03-02-2026 3:36pm EST
$81.10
$3.34
-3.96%
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
| Founded: | 1892 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 35.8B | IPO Year: | 2022 |
| Target Price: | $91.17 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 4.55 | EPS Growth: | 4.84 |
| 52 Week Low/High: | $57.65 - $89.77 | Next Earning Date: | 05-06-2026 |
| Revenue: | $20,625,000,000 | Revenue Growth: | 4.84% |
| Revenue Growth (this year): | 7.15% | Revenue Growth (next year): | 4.53% |
| P/E Ratio: | 18.56 | Index: | |
| Free Cash Flow: | N/A | FCF Growth: | -2.90% |
AI-Powered GEHC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.44%
74.44%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Call Transcripts for GE HealthCare Technologies Inc. (GEHC)
Historical SEC 8-K earnings filings with full transcript text
2025 Q4 Q4 2025 Earnings
8-K
Filed February 4, 2026
2025
Q4
Q4 2025 Earnings
8-KFiled February 4, 2026
Feb 4, 2026 0001932393-26-000006
gehc-202602040001932393false00019323932026-02-042026-02-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2026 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On February 4, 2026, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter 2025 and fiscal year ended December 31, 2025 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99 Press release of GE HealthCare Technologies Inc., dated February 4, 2026. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: February 4, 2026 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2025 Q3 Q3 2025 Earnings
8-K
Filed October 29, 2025
2025
Q3
Q3 2025 Earnings
8-KFiled October 29, 2025
Oct 29, 2025 0001932393-25-000052
gehc-202510290001932393false00019323932025-10-292025-10-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 29, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On October 29, 2025, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its third quarter 2025 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99 Press release of GE HealthCare Technologies Inc., dated October 29, 2025. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: October 29, 2025 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2025 Q2 Q2 2025 Earnings
8-K
Filed July 30, 2025
2025
Q2
Q2 2025 Earnings
8-KFiled July 30, 2025
Jul 30, 2025 0001932393-25-000048
gehc-202507300001932393false00019323932025-07-302025-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On July 30, 2025, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its second quarter 2025 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99 Press release of GE HealthCare Technologies Inc., dated July 30, 2025. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: July 30, 2025 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2025 Q1 Q1 2025 Earnings
8-K
Filed April 30, 2025
2025
Q1
Q1 2025 Earnings
8-KFiled April 30, 2025
Apr 30, 2025 0001932393-25-000013
gehc-202504300001932393false00019323932025-04-302025-04-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On April 30, 2025, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2025 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 8.01 Other Events. On April 30, 2025, the Board of Directors of GE HealthCare authorized a share repurchase program (the “program”) pursuant to which GE HealthCare may repurchase up to $1.0 billion of its common stock. The program does not have an expiration date. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99 Press release of GE HealthCare Technologies Inc., dated April 30, 2025. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: April 30, 2025 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2024 Q4 Q4 2024 Earnings
8-K
Filed February 13, 2025
2024
Q4
Q4 2024 Earnings
8-KFiled February 13, 2025
Feb 13, 2025 0001932393-25-000004
gehc-202502130001932393false00019323932025-02-132025-02-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter and fiscal year ended December 31, 2024 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99 Press release of GE HealthCare Technologies Inc., dated February 13, 2025. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: February 13, 2025 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2024 Q3 Q3 2024 Earnings
8-K
Filed October 30, 2024
2024
Q3
Q3 2024 Earnings
8-KFiled October 30, 2024
Oct 30, 2024 0001932393-24-000049
gehc-202410300001932393false00019323932024-10-302024-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On October 30, 2024, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its third quarter 2024 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99 Press release of GE HealthCare Technologies Inc., dated October 30, 2024. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: October 30, 2024 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2024 Q2 Q2 2024 Earnings
8-K
Filed July 31, 2024
2024
Q2
Q2 2024 Earnings
8-KFiled July 31, 2024
Jul 31, 2024 0001932393-24-000043
gehc-202407310001932393false00019323932024-07-312024-07-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On July 31, 2024, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its second quarter 2024 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated July 31, 2024. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: July 31, 2024 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2024 Q1 Q1 2024 Earnings
8-K
Filed April 30, 2024
2024
Q1
Q1 2024 Earnings
8-KFiled April 30, 2024
Apr 30, 2024 0001932393-24-000033
gehc-202404300001932393false00019323932024-04-302024-04-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On April 30, 2024, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2024 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated April 30, 2024. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: April 30, 2024 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2023 Q4 Q4 2023 Earnings
8-K/A
Filed February 6, 2024
2023
Q4
Q4 2023 Earnings
8-K/AFiled February 6, 2024
Feb 6, 2024 0001932393-24-000017
gehc-202402060001932393false00019323932024-02-062024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street,Chicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Introductory Note. This Amendment No. 2 to the Current Report on Form 8-K filed by GE HealthCare Technologies Inc. with the Securities and Exchange Commission on February 6, 2024 that reported the fourth quarter and fiscal year ended December 31, 2023 financial results is being amended to include the unaudited Consolidated and Combined Statements of Income for both the three months ended December 31, 2023 and 2022 and the three years ended December 31, 2023, 2022, and 2021 in Exhibit 99. Item 2.02 Results of Operations and Financial Condition. On February 6, 2024, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter and fiscal year ended December 31, 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated February 6, 2024. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: February 6, 2024 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2023 Q4 Q4 2023 Earnings
8-K/A
Filed February 6, 2024
2023
Q4
Q4 2023 Earnings
8-K/AFiled February 6, 2024
Feb 6, 2024 0001932393-24-000015
gehc-202402060001932393false00019323932024-02-062024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street,Chicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Introductory Note. This Amendment No. 1 to the Current Report on Form 8-K filed by GE HealthCare Technologies Inc. with the Securities and Exchange Commission on February 6, 2024 that reported the fourth quarter and fiscal year ended December 31, 2023 financial results is being amended to include the unaudited Consolidated and Combined Statements of Income for the three months ended December 31, 2023 and 2022 in Exhibit 99. Item 2.02 Results of Operations and Financial Condition. On February 6, 2024, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter and fiscal year ended December 31, 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated February 6, 2024. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: February 6, 2024 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2023 Q4 Q4 2023 Earnings
8-K
Filed February 6, 2024
2023
Q4
Q4 2023 Earnings
8-KFiled February 6, 2024
Feb 6, 2024 0001932393-24-000012
gehc-202402060001932393false00019323932024-02-062024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe Street,Chicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On February 6, 2024, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter and fiscal year ended December 31, 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated February 6, 2024. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: February 6, 2024 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2023 Q3 Q3 2023 Earnings
8-K
Filed October 31, 2023
2023
Q3
Q3 2023 Earnings
8-KFiled October 31, 2023
Oct 31, 2023 0001932393-23-000124
gehc-202310310001932393false00019323932023-10-312023-10-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe StreetChicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On October 31, 2023, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its third quarter 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated October 31, 2023. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: October 31, 2023 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2023 Q2 Q2 2023 Earnings
8-K
Filed July 25, 2023
2023
Q2
Q2 2023 Earnings
8-KFiled July 25, 2023
Jul 25, 2023 0001932393-23-000111
gehc-202307250001932393false00019323932023-07-252023-07-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe StreetChicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On July 25, 2023, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its second quarter 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated July 25, 2023. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: July 25, 2023 /s/ George A. Newcomb George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
2023 Q1 Q1 2023 Earnings
8-K
Filed April 25, 2023
2023
Q1
Q1 2023 Earnings
8-KFiled April 25, 2023
Apr 25, 2023 0001932393-23-000086
gehc-202304250001932393false00019323932023-04-252023-04-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe StreetChicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (833) 735-1139 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).☐ Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On April 25, 2023, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2023 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated April 25, 2023. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: April 25, 2023 /s/ George A. Newcomb George A. Newcomb, Chief Accounting Officer (authorized signatory)
2022 Q4 Q4 2022 Earnings
8-K
Filed January 30, 2023
2022
Q4
Q4 2022 Earnings
8-KFiled January 30, 2023
Jan 30, 2023 0001932393-23-000007
gehc-202301300001932393false00019323932023-01-302023-01-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware001-4152888-2515116 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.) 500 W. Monroe StreetChicago,IL 60661 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code) (617) 443-3400 ______________________________________________ (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share GEHC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Item 2.02 Results of Operations and Financial Condition. On January 30, 2023, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter and fiscal year ended December 31, 2022 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K. The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitDescription 99Press release of GE HealthCare Technologies Inc., dated January 30, 2023. 104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GE HealthCare Technologies Inc. (Registrant) Date: January 30, 2023 /s/ George A. Newcomb George A. Newcomb, Chief Accounting Officer (authorized signatory)
2022 Q4 Q4 2022 Earnings
8-K
Filed January 10, 2023
2022
Q4
Q4 2022 Earnings
8-KFiled January 10, 2023
Jan 10, 2023 0001932393-23-000004
gehc-202301060001932393false00019323932023-01-062023-01-06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 6, 2023
GE HEALTHCARE TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Delaware001-4152888-2515116
(State or other jurisdiction
of incorporation)(Commission
File Number)(IRS Employer
Identification No.)
500 W. Monroe StreetChicago,IL 60661
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code) (617) 443-3400
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.01 per share
GEHC
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition.
On January 10, 2023, GE Healthcare Technologies Inc. ("we" or "GE HealthCare") issued a press release announcing preliminary unaudited revenue results for the fourth quarter and fiscal year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The preliminary revenue results provided do not present all information necessary for a complete understanding of our earnings results for the fiscal year ended December 31, 2022.
Item 7.01 Regulation FD Disclosure.
As part of the press release, we reaffirmed portions of our outlook for 2022 and provided components of our outlook for 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished pursuant to Items 2.02 and 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On January 6, 2023, our board of directors determined to hold our first annual meeting of stockholders (the "2023 Annual Meeting") virtually at 9:00 a.m. CT on Tuesday, May 23, 2023. The record date for the meeting is March 27, 2023. Deadlines for submission of nominations and stockholder proposals are set out below. In accordance with our Bylaws, stockholder proposals and nominations should be sent to GE HealthCare Technologies Inc., 500 W. Monroe Street, Chicago, Illinois, 60661, Attention: Secretary.
•Deadline for Rule 14a-8 Stockholder Proposals: Consistent with the Securities and Exchange Commission's proxy rules, we have set January 20, 2023 as the deadline for receipt of proposals to be included in our proxy materials for the 2023 Annual Meeting.
•Deadline for Other Stockholder Proposals: In accordance with our Bylaws, notice of stockholder proposals intended to be presented at, but not included in proxy materials for, the 2023 Annual Meeting, including director nominations for election to our board of directors (other than "proxy access" director nominations) must be received no earlier than January 23, 2023 and no later than February 22, 2023. Notice must also comply with the other requirements in our Bylaws and other applicable law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription
99.1
Press Release of GE HealthCare Technologies Inc., dated January 10, 2023.
104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exch Latest GE HealthCare Technologies Inc. News
GEHC Breaking Stock News: Dive into GEHC Ticker-Specific Updates for Smart Investing
MarketBeat
GE HealthCare Teases 2027 Imaging Revenue Boost, Reaffirms 2026 Growth as Tariff Risks Loom
📊
AI Sentiment
Positive
6/10
Zacks
GEHC & UCSF Form 10-Year Alliance to Advance Imaging & Care Delivery
📈
AI Sentiment
Highly Positive
8/10
StockStory
2 Nasdaq 100 Stocks with Exciting Potential and 1 We Question
➖
AI Sentiment
Neutral
4/10
Zacks
GEHC Unveils AI LOGIQ Ultrasound Systems to Boost Imaging & Workflow
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Is Covista’s Purpose at Scale Revenue Plan Reshaping The Investment Case For Covista (CVSA)?
📈
AI Sentiment
Highly Positive
8/10
Compare GEHC vs Leading Stocks
See how GEHC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GEHC GE HealthCare Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.